This study aimed to analyze the efficacy of topical GM-CSF (molgramostim) vs. the combined topical use of an antiseptic agent (povidone-iodine) and amphotericin B (AA) in patients with chemotherapy-induced mucositis (World Health Organization; WHO) grades I–III. This evidence concerns the gene CSF2 and mucositis.